Chamber and committees

Today the Medicines and Healthcare products Regulatory Agency has issued a Caution in Use Notice alert, reporting that a number of injectable naloxone kits have been supplied across the UK, including Scotland, which may have missing needles.

The product, Prenoxad ® , is an injectable form of naloxone. A pack normally contains two needles. The problem emerged when it was reported that a very limited number of Prenoxad ® packs in a batch marketed in France were missing needles. This was the case in three packs out of a batch of 9,000.

Although I have received no reports of UK packs with missing needles to date, the potential for packs to contain fewer than two needles in all distributed batches cannot be ruled out. We do know, however, that kits from batches that could potentially be affected have been distributed in Scotland and we are therefore advising people to check their kits and to replace any that are incomplete.

In response to the Caution in Use Notice, the Scottish Government has taken immediate action to advise healthcare professionals on how to identify and replace kits which may have been supplied without needles.

In addition, we have issued guidance on this to third sector partners who have been distributing kits to individuals. We are also working with stakeholders to produce clear, illustrated guidance on how people can check their kits, for third sector partners and others to share with people who carry their own naloxone kits.

I am acting quickly to ensure that kits are complete, because the wide supply and carriage of naloxone is a key part of our National Mission to improve and save lives. Naloxone remains a safe medication to use in response to a life-threatening overdose and I am determined that this potential defect should not disrupt its use in Scotland or reduce public confidence in the naloxone programme.